文献速递泌尿生殖与妇科肿瘤放疗

ONE SHOT——单次放疗治疗局限性前列腺癌:单臂多中心I/II期试验研究方案

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
PubMed 文献 · Radiat Oncol · 2018-09-04

该多中心I/II期前瞻性试验针对低危和中危局限性前列腺癌患者,采用单次SBRT 19 Gy照射全前列腺、尿道保护17 Gy,以CTCAE 4.03评估的的安全性为I期主要终点、生化无复发生存为II期主要终点,旨在初步验证单次SBRT的安全性和疗效。

要点

  • 低危和中危局限性前列腺癌、移行区无明显肿瘤的患者接受单次SBRT 19 Gy,尿道保护至17 Gy。
  • I期主要终点为CTCAE 4.03评估的安全性,II期主要终点为生化无复发生存。
  • 这是首个评估单次SBRT治疗局限性前列腺癌的多中心I/II期试验。

核心结论

  • 这是首个评估单次SBRT治疗局限性前列腺癌疗效与安全性的多中心I/II期试验。
  • 若结果阳性,ONE SHOT的结果可能有助于设计后续III期试验,探索SBRT单药在局限性前列腺癌根治性放疗中的作用。

研究设计与样本

  • 多中心、单臂、前瞻性I/II期试验,纳入低危和中危局限性前列腺癌且移行区无明显肿瘤的患者。
  • 单次SBRT照射全前列腺19 Gy,尿道保护剂量17 Gy,采用前列腺内电磁传感器监测分次内运动。
  • I期主要终点为CTCAE 4.03分级评估的安全性,II期主要终点为生化无复发生存。
  • 次要终点包括急性和晚期毒性、生活质量、无进展生存和前列腺癌特异性生存。
  • 试验注册号NCT03294889,注册日期2017年9月27日。

关键数值与推荐

  • 单次SBRT剂量为全前列腺19 Gy,尿道保护剂量为17 Gy。
  • 安全性采用CTCAE 4.03分级量表评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic body radiotherapy (SBRT) is an emerging treatment alternative for patients with localized prostate cancer. Promising results in terms of disease control and toxicity have been reported with 4 to 5 SBRT fractions. However, question of how far can the number of fractions with SBRT be reduced is a challenging research matter. As already explored by some authors in the context of brachytherapy, monotherapy appears to be feasible with an acceptable toxicity profile and a promising outcome. The aim of this multicenter phase I/II prospective trialis to demonstrate early evidence of safety and efficacy of a single-fraction SBRT approach for the treatment of localized disease. METHODS: Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone will be treated with a single SBRT fraction of 19 Gy to the whole prostate gland with urethra-sparing (17 Gy). Intrafractional motion will be monitored with intraprostatic electromagnetic transponders. The primary endpoint of the phase I part of the study will be safety as assessed by CTCAE 4.03 grading scale, while biochemical relapse-free survival will be the endpoint for the phase II. The secondary endpoints include acute and late toxicity, quality of life, progression-free survival, and prostate-cancer specific survival. DISCUSSION: This is the first multicenter phase I/II trial assessing the efficacy and safety of a single-dose SBRT treatment for patients with localized prostate cancer. If positive, results of ONE SHOT may help to design subsequent phase III trials exploring the role of SBRT monotherapy in the exclusive radiotherapy treatment of localized disease. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03294889 ; Registered 27 September 2017.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zilli T, Scorsetti M, Zwahlen D, et al. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiat Oncol. 2018. PMID: 30180867. doi:10.1186/s13014-018-1112-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。